Answers are grounded in this paper and cite their sources.
Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m
No takes yet. Share an insight, caveat, or question.
Izutsu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: